Lacosamid Fresenius Kabi (Lacosamide)

Lacosamide, the active ingredient in Lacosamid Fresenius Kabi, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats partial‑onset seizures and is used as adjunct therapy in epilepsy patients who require additional seizure control.

GNH USA supplies Lacosamid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: Reduces seizure frequency as adjunctive therapy in focal epilepsy. - Epilepsy (generalized): Used as add‑on treatment for patients whose seizures are not controlled by other antiepileptic drugs. - Status epilepticus (IV): Provides rapid seizure control when administered intravenously in emergency settings.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness: Sensation of light‑headedness or unsteadiness. - Fatigue: General feeling of tiredness or lack of energy. - Nausea: Stomach discomfort often accompanied by an urge to vomit. - Headache: Mild to moderate pain in the head region.

Serious or Rare Side Effects: - Cardiac arrhythmia (PR‑interval prolongation): May lead to heart rhythm disturbances. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): Requires immediate medical attention. - Suicidal ideation: Emergence of thoughts of self‑harm. - Anaphylaxis: Acute allergic reaction with potential airway compromise.

When using Lacosamid Fresenius Kabi, consider the following precautions.

- Renal impairment: Monitor renal function and adjust therapy as needed. - Hepatic impairment: Use with caution; liver dysfunction may affect drug clearance. - Cardiac conduction: Perform ECG monitoring for PR‑interval changes. - Pregnancy: Safety unknown; weigh potential benefits against risks. - Concomitant CNS depressants: Observe for enhanced sedation or respiratory depression. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Lacosamide may interact with other medicines.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): May cause severe PR‑interval prolongation. - Carbamazepine: Induces metabolism, reducing lacosamide effectiveness.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., phenytoin, phenobarbital): Potential additive CNS depression. - CYP3A4 inhibitors (e.g., erythromycin): Can increase lacosamide plasma levels. - Alcohol: May enhance dizziness and somnolence.